Creative Medical Technology issues mid-year pipeline update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Creative Medical Technology Holdings Issues Mid-Year Update
July 1, 2026 9:00 AM EDTPHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (Creative Medical or the Company), a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.
Dear Fellow Shareholder:
Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (OA), immunotherapy, and biodefense.
This progress, combined with disciplined capital allocation and expanding non-dilutive opportunities, positions the Company for durable value creation... More
